SOX2 and glioblastoma: Thus, dominant negative activity of SES can also be detrimental to GBM subtypes or subclones that develop SOX2 independence, as, for instance, in the mesenchymal transition occurring upon current clinical treatments (15–18), in which an approach based on simple SOX2 knockdown is ineffective.